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Role of Chronic Inflammation as a Predictor of Upstaging/Upgrading in Prostate Cancer: 
Finding A New Group Eligible for Active Surveillance
Mohammad Reza Nowroozi, Mohsen Ayati, Erfan Amini, Seyed Majid Aghamiri, Seyed Ali Momeni, Solmaz 
Ohadian Moghadam, Farzin Valizadeh*
Purpose: We aimed to investigate the correlation between presence of inflammation and pathology upgrading/
upstaging in patients with prostate cancer.
Materials and Methods: A retrospective study was accomplished on 315 patients with prostate cancer, eligible for 
active surveillance except prostate-specific antigen (PSA) level (PSA<30ng/dL), who underwent radical prostatec-
tomy between 2005 and 2015. Patients were divided into two groups based on needle biopsy: A; with evidence of 
inflammation (chronic prostatitis) and B; without inflammation. The frequency of upstaging and upgrading in both 
groups was compared in different ranges of PSA level (<10, 10-20 and 20-30ng/dL). Upgrading/Upstaging was 
defined as increase from one prognostic grade group to another. Statistical analyses were performed to investigate 
the relation between inflammation and upgrading/upstaging.
Results: The mean age of the patients was 68.2 years and the mean PSA level was 10.2 ng/mL. Chronic prostatitis 
was identified in 82 of 315 cases therefore upgrading/upstaging were seen in only three patients (3.7%) while 39 
of 233 (16.7%) patients without inflammation had upgrading/upstaging in final pathology (P = 0.003). Other vari-
ables including the patient's PSA before surgery, PSA density, and the presence of hypoechoic areas in ultrasound 
had a significant relationship with the incidence of postoperative upgrading/upstaging. Among studied variables, 
presence of inflammation in biopsies was found to be the most important predictor of upstaging/upgrading (OR: 
0.205).
Conclusion: Our data demonstrated that patients with concurrent prostatitis and PCa may have a better prognosis 
even if the PSA level is higher than 10ng/mL.
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INTRODUCTION
Prostate cancer is considered as the most common cancer and the second most common cause of can-
cer-related mortality in adult men and the incidence of 
disease is increasing globally(1, 2). Due to widespread 
use of PSA screening, the number of diagnosed prostate 
cancer patients has increased in recent years. However, 
many patients may receive unnecessary treatments for 
clinically localized and insignificant cancer(3, 4). 
Active surveillance is considered as a management 
method for low-risk prostate cancer but the main chal-
lenge is to determine low risk prostate cancer patients. 
Therefore, in order to achieve an accurate prediction of 
pathologic stage, it is necessary to have more sensitive 
markers and more accurate criteria. We conducted this 
study to evaluate baseline factors that might predict 
upstaging/upgrading in those who are candidates for 
active surveillance. One of the baseline characteristics 
that has the potential to predict upstaging/upgrading is 
the presence of chronic prostatitis in biopsy specimens. 
Prostate specific antigen (PSA) is elevated in patients 
with chronic prostatitis and this elevation though relat-
ed to inflammation may erroneously exclude patients 
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from active surveillance program(5-7). We hypothesized 
that presence of chronic prostatitis may overestimate 
the risk of disease and therefore patients with chronic 
prostatitis and higher serum PSA levels who are oth-
erwise appropriate for active surveillance may benefit 
from surveillance. 
PATIENTS AND METHODS
Our institution prospectively records demographic, 
clinical, and pathological data for patients who under-
go radical prostatectomy for prostate cancer. Among 
all men who underwent radical prostatectomy between 
2005 and 2015, 213 patients had PSA ≤ 10 ng/mL, clin-
ically localized prostate cancer (cT1), biopsy Gleason 
score ≤ 6 and involvement of 2 cores or less and met 
inclusion criteria for active surveillance. Patients with 
total biopsy cores less than 12 were excluded from anal-
ysis. In addition, 84 patients with PSA level between 
10 and 30 ng/mL who met the remaining criteria for 
active surveillance were also included in the analysis 
to assess the possibility of expanding criteria for active 
surveillance. Upstaging and upgrading were defined as 
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pathologic stage ≥ T3 and presence of Gleason pattern 
4 in radical prostatectomy specimens. Incidence of up-
staging/upgrading was determined in both groups and 
the impact of baseline characteristics in predicting up-
staging/upgrading was evaluated. 
All baseline characteristics including age, Body mass 
index (BMI), pre-operative PSA, prostate volume, PSA 
density, transition zone volume, PSA transition zone 
density, Gleason score, presence of hypoechoic lesions 
in ultrasound and chronic inflammation in biopsy speci-
mens were compared between patients with and without 
upstaging/upgrading. 
Clinical staging was determined based on digital rectal 
exam findings, whole body bone scan and cross sec-
tional imaging (MRI or CT). In our institution, patients 
with low risk prostate cancer also routinely undergo 
bone scan and cross sectional imaging prior to surgery. 
Chronic prostatitis was defined according to the consen-
sus classification system proposed by Nickel et al. and 
was defined as presence of multifocal stromal, glandu-
lar or periglandular infiltration with inflammatory cells, 
including lymphocytes, plasma cells and macrophages.
Multivariable analysis was also performed to assess 
which factors can independently predict upstaging/up-
grading in each PSA category.
Statistical analysis
The results for quantitative variables were expressed 
as the mean and standard deviation (mean ± SD) and 
for qualitative variables as percentages. Kolmogor-
ov-Smirnov (K-S) test was used to evaluate the normal 
distribution of quantitative variables. In the case of 
normal distribution, the comparison of the mean quan-
titative variables in two qualitative groups was done by 
independent t-test. The comparison between qualitative 
variables was done using Chi-square test or Fisher's 
exact test. Furthermore, for examining the predictive 
power of variables, binary logistic regression analysis 
was done. Data analyses were performed using Package 
for Social Sciences (SPSS) version 16. The p values of 
< 0.05 were considered significant.
RESULTS
In this study, 273(87%) patients had no upstaging/up-
grading postoperatively, and only 42 (13%) patients 
showed upstaging/upgrading. Table 1 compares base-
line characteristics between the study groups. As shown 
in the table, PSA, PSA density, presence of hypoechoic 
lesion and chronic prostatitis has the potential to predict 
upstaging/upgrading. Upstaging/upgrading was more 
frequent among patients with hypoechoic lesion in ul-
trasound compared to those who did not show hypo-
echoic lesion (20.4% vs. 9.9% respectively; P = 0.010), 
whereas it was less frequent in patients with chronic 
prostatitis (3.7% upstaging/upgrading in patients with 
chronic prostatitis vs. 16.7% in patients without prosta-
titis, P = 0.003). 
In a second analysis, we assessed the impact of chronic 
prostatitis and hypoechoic lesions on predicting upstag-
ing/upgrading in patients with PSA>10 ng/mL.
In patients with PSA between 10 and 30 ng/mL, chronic 
prostatitis was significantly associated with upstaging/
upgrading. Among 24 patients with chronic prostatitis 
and PSA>10, only 2(8.3%) showed upstaging/upgrad-
ing whereas reclassification happened in 19 (31.7%) 
patients without prostatitis (P = 0.026). We found no 
statistically significant association between hypoechoic 
lesions and upstaging/upgrading in patients with serum 
PSA>10.
Multivariable logistic regression analysis also showed 
that serum PSA level, presence of hypoechoic lesions 
and chronic prostatitis can independently predict up-
staging/upgrading in potential candidates for prostate 
cancer active surveillance.
Table 1. Comparing baseline characteristics between study groups.
       Upstaging/Upgrading   P-Value
       Present   Absent 
Age mean(SD)      69.5(9.0)  68.0(8.2)  0.29*
BMI mean(SD)      25.23(4.02)  25.58(3.39)  0.37*
Prostate Volume mean(SD)     38.60(17.77)  35.52(17.87  0.21*
PSA mean(SD)      15.33(8.32)  9.46(4.84)  < 0.001*
PSA Density mean(SD)     0.47(0.36)  0.33(0.21)  0.039*
PSA Transition Zone Density mean(SD)    0.99(1.71)  0.72(2.51)  0.238*
Hypoechoic lesion in transrectal ultrasound
Number (%) Present     21(20.4)  82(79.6)  0.010†
  Absent     21(9.9)  191(90.1) 
Chronic prostatitis in biopsy specimen
Number (%) Present     3(3.7%)  79(96.3%)  0.003†
  Absent     39(16.7%)  194(83.3%) 
* Independent T-test 
† Chi-square test
      Hazard ratio (95% CI)  P-value
PSA  ≤10 ng/mL (referent)  3.517 (1.757-7.039)  < 0.001
  10-30  
Hypoechoic lesion Absent (referent)  2.231(1.120-4.443)  0.022
  Present  
Inflammation Absent (referent)  0.171(0.050-0.580)  0.005
  Present  
Table 2. Binary logistic regression analysis to determine independent predicting factors of upgrading/upstaging.
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DISCUSSION
In the present study we showed that presence of chronic 
inflammation in association with prostate cancer in bi-
opsy specimens may be a predictor of low risk disease 
and many of these patients can be a suitable candidate 
for AS regardless of serum PSA level. It also should be 
considered that there is no consensus on the role of PSA 
level in predicting outcomes and GS is considered as 
the most important factor for treatment decision mak-
ing(11). Therefore, in contrast to Epstein’s criteria for 
AS, some patients with elevated serum PSA level, even 
those with PSA between 20 and 30, may be suitable 
candidate for AS.
In the current study, the upgrading/upstaging rate be-
tween patients with preoperative PSA level less than 
10 ng/mL and patients with PSA level between 10 and 
20 ng/mL had a significant difference. However, those 
with chronic inflammation had a significantly lower 
risk of upstaging/upgrading.
The previous study by Faisal et al., showed that patients 
with PSA between 10 and 20 ng/mL could not be con-
sidered as suitable candidates for the Active Surveil-
lance management strategy. Moreover, they suggested 
that concurrent existence of prostate cancer and pros-
tatitis may make these patients candidates for AS(12). 
Moreover, those with PSA density < 0.15 ng/mL/gr are 
appropriate cases for AS. This simply means patients 
with more prostate volume will be less likely to be at 
risk(12). Besides, Kwak et al. have shown that increased 
prostate volume was associated with the severity of 
inflammation(13). On the other hand, Jiwoon Yu et al., 
concluded that upstaging/upgrading in patients with 
PSA level >20 ng/mL was significantly higher than pa-
tients with a PSA level <20 ng/mL(14). However, Spahn 
M et al., suggested that 10 year mortality rate for pros-
tate cancer with PSA >20 ng/ml and Gleason score ≤7 
or GS>7 is 5% and 35% respectively(15). 
Considering histological inflammation in needle biop-
sy sample and serum PSA level of non-prostate can-
cer men, Okada K et al. proposed that aging, prostate 
volume and histological evidence of inflammation were 
significantly associated with increased levels of PSA, 
especially in those with a larger prostate(15). This was 
in contrary to the study of Chang SG et al., in which 
they found that the chronic inflammation of prostate 
is not associated with increased PSA level and pros-
tate volume mentioned as the most important cause of 
increased serum PSA levels in patients with negative 
prostate biopsy for cancer(17). 
Our results revealed that among studied factors, pres-
ence of inflammation as well as hypoechoic areas in 
ultrasound, and PSA are the parameters that are signif-
icantly associated with upstaging/upgrading. Addition-
ally, binary logistic regression showed that the presence 
of inflammation and hypoechoic lesions are independ-
ent factors that have the potential for predicting upgrad-
ing/upstaging. The retrospective nature was one of the 
limitations of the current study. 
CONCLUSIONS
Our study showed that the presence of inflammation 
in biopsies as well as presence of hypoechoic areas in 
ultrasound are independent predictors of upstaging/up-
grading. The presence of inflammation in the prostate 
tissue is associated with a reduced risk of prostate can-
cer. Therefore, concurrent prostatitis and an elevated 
PSA level (>10 ng/mL) can lead to an error in selection 
of patients for the AS strategy. 
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